The Ruth and Bruce Rappaport Faculty of Medicine
Departments Academic Programs Phone Book Faculty Services American Program Photo Gallery Forms Contact Us
  Home   >   Preclinical   >   Department of Molecular Pharmacology   >   Academic Staff
 Department of Molecular Pharmacology    
Professor Emeritus Moussa Youdim
Location: קומה 2
Tel: 972-4-829-5289
Fax: 972-4-851-3145
 Main Research Area
Eve Topf and National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Teaching is an independent extension of the Department of Pharmacology at Technion-Rappaport Faculty of Medicine and has a close interaction with Rappaport Family Research Institute. It is dedicated in advancing the understanding of neuropsychiatric disorders, specially, neurodegenerative diseases. The centers main focus is to elucidate why and how neurons degenerate, employing cellular and animal models and to develop novel drugs to prevent or rescue them. This is accomplished by implementation of conventional and novel biochemical techniques combined with chemistry molecular biology, genomics and proteomics. This has led to identification and development of several novel neuroprotective anti-Parkinson and anti-Alzheimer drugs including rasagiline, TV3326 and (-)-epigallocatechin-3-gallate (EGCG). The Centers have close relationships and collaborations with Teva Pharmaceutical Co. (Israel) and a number of major institutes in Israel and abroad. Together with the Technion, Eve Topf Center is co-founder of Varinel Inc. (USA) which has developed novel brain permeable neuroprotective bifunctional iron chelators-monoamine oxidase (MAO) inhibitors for the treatment of neurodegenerative and systemic diseases, where misregulation of iron metabolism is implicated.
 Journal articles
   Click here for a list of available publications in PubMed.
 Graduate students
Lydia Reznichenko
Studies towards Ph.D. Email:
Neurorescue properties of the green tea polyphenol (-)-epigalloctechin-3-gallate (EGCG) in cell culture and animal models of Parkinson''s Disease, alone and in cocktail with neuroprotective drugs.
Yael Chertkow
Studies towards Ph.D. Email:
The effects of typical and atypical antipsychotics alone and in combination with '+chr(39)+'SSRI antidepressant on gene and protein expression and their relationship to clinical efficacy in schizophrenia.
Yotam Sagi
Studies towards Ph.D. Email:
Pharmacological and molecular mechanisms of neuroprotectorals anti-Alzheimer and anti-Parkinson''s drugs TV3326, TV3279 and rasagiline.
Limor Kalfon-Tal
Studies towards Ph.D. Email:
Molecular Mechanisms and Signaling Pathways Mediating the Neuroprotective Action of the Green Tea Polyphenol, (-)-Epigallocatechin 3-Gallate (EGCG)
Merav Yogev-Falach
Studies towards Ph.D. Email:
Amyloid precursor protein processing and neuroprotection by the '+chr(39)+'anti-alzheimer''s drug, Ladostigil (TV3326)
Noam Drigues
Studies towards MD-Ph.D. Email:
Gene Expression Profile in Rat Hippocampus After Chronic Administration of Antidepressant Drugs.
Shunit Ben-Ari (Gal)
Studies towards Ph.D. Email:
Novel multifunctional beuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases.
Yael Avramovich-Tirosh
Studies towards Ph.D. Email:
Neurorescue mechanisms and processing of the Alzheimer''s disease APP by novel multi- functional iron- chelator drugs.
Merav Oren
Studies towards M.Sc. Email:
\"Neuroprotection by novel iron chelator in the kainic acid model of neurodegeneration \"
Ayelet Blank
Studies towards M.Sc. Email: